The C-Reactive Protein Levels in Left Ventricular Dysfunction of Different Etiology

Anzulovic-Mirosevic, Dinko; Razzolini, Renato; Zaninotto, Martina; Plebani, Mario; Mion, Monica; Rozga, Ante; Dalla‐Volta, Sergio

doi:10.2174/187152809789352212

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the role of systemic inflammation is established in ischemic heart disease, holding a central place in the initiation and progression of atherosclerosis [ 5 , 6 , 7 ], less is known about its role in non-ischemic cardiomyopathies. A previous study on 59 patients with left ventricular dysfunction of different aetiology showed significantly higher CRP levels in patients with ischemic left ventricular dysfunction than in those with non-ischemic left ventricular dysfunction, and that acute myocardial infarction is associated with higher CRP levels than chronic left ventricular dysfunction [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

A Machine-Learning Model for the Prognostic Role of C-Reactive Protein in Myocarditis

Baritussio

Cheng

Lorenzoni

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Aims: The role of inflammation markers in myocarditis is unclear. We assessed the diagnostic and prognostic correlates of C-reactive protein (CRP) at diagnosis in patients with myocarditis. Methods and results: We retrospectively enrolled patients with clinically suspected (CS) or biopsy-proven (BP) myocarditis, with available CRP at diagnosis. Clinical, laboratory and imaging data were collected at diagnosis and at follow-up visits. To evaluate predictors of death/heart transplant (Htx), a machine-learning approach based on random forest for survival data was employed. We included 409 patients (74% males, aged 37 ± 15, median follow-up 2.9 years). Abnormal CRP was reported in 288 patients, mainly with CS myocarditis (p < 0.001), recent viral infection, shorter symptoms duration (p = 0.001), chest pain (p < 0.001), better functional class at diagnosis (p = 0.018) and higher troponin I values (p < 0.001). Death/Htx was reported in 13 patients, of whom 10 had BP myocarditis (overall 10-year survival 94%). Survival rates did not differ according to CRP levels (p = 0.23). The strongest survival predictor was LVEF, followed by anti-nuclear auto-antibodies (ANA) and BP status. Conclusions: Raised CRP at diagnosis identifies patients with CS myocarditis and less severe clinical features, but does not contribute to predicting survival. Main death/Htx predictors are reduced LVEF, BP diagnosis and positive ANA.

show abstract

Section: Discussionmentioning

confidence: 99%

A Machine-Learning Model for the Prognostic Role of C-Reactive Protein in Myocarditis

Baritussio

Cheng

Lorenzoni

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Anzulovic-Mirosevic et al have shown that C-reactive protein levels are increased in adult patients with non-ischemic cardiomyopathy proportionate to the severity of the symptoms and systolic impairment. 15 Furthermore, in situ hybridization experiments have shown significant myocardial production of C-reactive protein mRNA in cardiomyocytes of patients with non-ischemic cardiomyopathy. 16 Interestingly, hsCRP in UVD patients was found to be more indicative of HF in those patients with left ventricular morphology and those at the second stage of palliation.…”

Section: Discussionmentioning

confidence: 99%

High sensitivity C-reactive protein: a biomarker for heart failure in children with univentricular heart disease

Lowenthal¹,

Natal-Hernandez²,

Lowenthal³

et al. 2012

CBF

View full text Add to dashboard Cite

Children with univentricular congenital heart disease are at increased risk for developing heart failure. However, detecting early heart failure in these patients is especially difficult because few objective measures have been validated in this cohort. The aim of this study is to determine the usefulness of high sensitivity C-reactive protein (hsCRP) as a biomarker for detecting heart failure in univentricular heart disease patients, and to define the impact of univentricular morphology and stage of palliation on its utility. A cross-sectional observational study of children with univentricular congenital heart disease aged 1 month to 7 years was conducted. The presence of heart failure was defined as a Ross score . 2. The association of hsCRP with heart failure was assessed using logistic regression and receiver operating characteristic curves. Of the 50 included children, 16 (32%) had clinical heart failure. A doubling of hsCRP resulted in a 0.31 unit increase in Ross score (95% confidence interval: -0.07, 0.56; P = 0.01) with a c-statistic of 68%. When stratified by ventricular morphology, the left univentricular morphology group exceeded the threshold of $75% (c-statistic = 81%) as did those at stage II of palliation (c-statistic = 85%). A cut point of $0.8 mg/mL correctly classified 75% of patients with left univentricular morphology, and 73% of patients regardless of morphology at stage II of palliation. From these results, we conclude that hsCRP is a useful biomarker of clinical heart failure in univentricular patients with left ventricular morphology at all stages of surgical palliation, and in all univentricular patients at stage II of palliation.

show abstract

“…Over the years, the occurrence of inflammation in chronic heart failure (CHF) and acute myocardial infarction (AMI) has been widely described. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]. Consistent data indicate fluctuations in cytokine levels in patients with a reduced left ventricular function.…”

Section: Introductionmentioning

confidence: 90%

Cytokines and the Role of Immunomodulation in Heart Failure of Different Etiologies

Anzulovic-Mirosevic¹,

Zaninotto²,

Mion³

et al. 2018

ARC Journal of Cardiology

View full text Add to dashboard Cite

For some time now, scholars have been describing a number of activation patterns of the immune response in the acute phase of myocardial infarction. What has been less studied are the modifications concerning both chronic ischemic patients with the chronic ischemic cardiomyopathy and patients with heart failure of any aetiology. It would, therefore, be of utmost importance to analyse and understand the impact of the factors regulating the immune response during longer intervals of time, starting with the acute phase. Since the therapeutical approach has, until now, failed to produce a positive resultas has been the case with tumor necrosis factor α (TNF-α) inhibitorswe believed that a pharmaceutical approach, involving a modulation of other immune response pathways could have a higher probability of producing more successful results. For these reasons we studied the following group of patients: 44 subjects (male to female ratio 6,33), ranging from 40 to 80 years, mean age 61, SD 9,8, with left ventricular dysfunction caused by different cardiac disorders, and a group of 29 healthy individuals as a control group. The levels of a number of biochemical markers (tumor necrosis factor alpha, TNF-α; interferon γ, IFN-γ; interleukin-6, IL-6; interleukin-10, IL-10) were analysed and compared in the patient and the control group. Statistically significant differences in the levels of IFN-γ and IL-6 between the chronic patients and the healthy controls were observed (IFN-γ 180,

show abstract

The C-Reactive Protein Levels in Left Ventricular Dysfunction of Different Etiology

Cited by 6 publications

References 0 publications

A Machine-Learning Model for the Prognostic Role of C-Reactive Protein in Myocarditis

A Machine-Learning Model for the Prognostic Role of C-Reactive Protein in Myocarditis

High sensitivity C-reactive protein: a biomarker for heart failure in children with univentricular heart disease

Cytokines and the Role of Immunomodulation in Heart Failure of Different Etiologies

Contact Info

Product

Resources

About